Drug Database
Back to search

Denmark· DK-28105692615

Glyxambi

A linagliptin and empagliflozin product containing empagliflozin, linagliptin, registered in Denmark by Boehringer Ingelheim Int. GmbH. The same ATC class is registered in 13 of our 19 countries.

ATC A10BD19

Checked against Danish Medicines Agency (Denmark) on

Informational only — not a medical device.

SOURCE REGISTER · DKDanish Medicines Agency (Denmark)normalisedGlyxambiATCA10BD19REGISTER NO.DK-28105692615PACKS LISTED1CHECKEDSeptember 30, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about empagliflozin, linagliptinAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Linagliptin and empagliflozin is registered in 13 of 19 countries.

Countries holding a registration under ATC A10BD19 (linagliptin and empagliflozin), each read from that country’s own register.

  • This record: Denmark, from Danish Medicines Agency (Denmark)
  • 9 of them publish a price we can compare per daily dose
Search linagliptin and empagliflozin products by name

Linagliptin and empagliflozin · ATC A10BD19

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Danish Medicines Agency (Denmark)
Active substance
Empagliflozin, Linagliptin
Manufacturer
Boehringer Ingelheim Int. GmbH
Country
Denmark (DK)
ATC code
A10BD19
ATC class
Linagliptin and empagliflozin
Reimbursed
Not published by this register
Source register
Danish Medicines Agency (Denmark)
Last checked
September 30, 2026

Packs & prices · 1

  • dk_varenummer
    28105692615

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under A10BD19

Linagliptin and empagliflozin, as other registers publish it.

All linagliptin and empagliflozin products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b508a5bd-0894-4a9e-a751-926b617b7b65
GET /v1/drugs/b508a5bd-0894-4a9e-a751-926b617b7b65?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "filmovertrukne tabletter",
  "source": "dkma",
  "strength": "25 mg+5 mg",
  "auth_role": "MOD",
  "dk_drugid": "28105692615",
  "substance": "Empagliflozin, Linagliptin",
  "auth_procedure": "Central",
  "in_medicinpriser": false,
  "registration_date_serial": "42685"
}
API referenceMCP serverPlans

See everything about linagliptin and empagliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console